Vimarsana
Biggest News Aggregation in the World

Physical Impacts News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Physical Impacts. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Physical Impacts Today - Breaking & Trending Today

Possible Mental Health Risks Caused by Loneliness - Vimarsana News

Possible Mental Health Risks Caused by Loneliness

Loneliness poses hidden risks and affects people's mental health, resulting in a lower quality of life.

FDA Approves Sotatercept, First-in-Class Treatment for Adults With PAH - Vimarsana News

FDA Approves Sotatercept, First-in-Class Treatment for Adults With PAH

Adults with pulmonary arterial hypertension (PAH) have a new treatment available with the FDA approval of sotatercept (Winrevair; Merck), an activin signaling inhibitor biologic.

Source: ajmc.com
Addressing Period Poverty in Niger - The Borgen Project - Vimarsana News

Addressing Period Poverty in Niger - The Borgen Project

Statistics and Physical Impacts of Period Poverty in Niger: United Nations Women of Africa conducted a study on menstrual hygiene in Niger...

Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH) - Vimarsana News

Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)

Application based on clinically meaningful results from the Phase 3 STELLAR trial If approved, sotatercept would be the first in its class, bringing a novel approach to address a rare and...

Sotatercept Improves Exercise Capacity in Individuals With Pulmonary Arterial Hypertension - Vimarsana News

Sotatercept Improves Exercise Capacity in Individuals With Pulmonary Arterial Hypertension

The median change from baseline at week 24 in the 6-minute walk distance was 34.4 m in the sotatercept group and 1 m in the placebo group among patients with pulmonary arterial hypertension.